



Universiteit
Leiden
The Netherlands

TCRs as precision tools against B-cell and plasma cell malignancies

Meeuwsen, M.H.

Citation

Meeuwsen, M. H. (2024, October 1). *TCRs as precision tools against B-cell and plasma cell malignancies*. Retrieved from <https://hdl.handle.net/1887/4093497>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/4093497>

Note: To cite this publication please use the final published version (if applicable).

TCRs as Precision Tools against B-cell and Plasma Cell Malignancies

Miranda Meeuwsen

ISBN: 978-94-6496-168-3

Cover design: Miranda Meeuwsen

Lay-out: Ilse Modder | www.ilsemodder.nl

Printed by: Gildeprint Enschede | www.gildeprint.nl

The research presented in this thesis was performed at the Department of Hematology of the Leiden University Medical Center and was financially supported by KWF kankerbestijding (grant number KWF UL-2014-6831) and Onderzoeksfonds Hematon (grant number FS 2018-2).

© 2024 M.H. Meeuwsen

All rights reserved. No part of this thesis may be reproduced or transmitted in any form or by any means without prior written permission of the author.

TCRs as Precision Tools against B-cell and Plasma Cell Malignancies

Proefschrift

ter verkrijging van
de graad van doctor aan de Universiteit Leiden,
op gezag van rector magnificus prof.dr.ir. H. Bijl,
volgens besluit van het college voor promoties
te verdedigen op dinsdag 1 oktober 2024
klokke 16.00 uur

door

Miranda Hester Meeuwsen
geboren te Zwijndrecht
in 1992

Promotores

Prof. dr. J.H.F. Falkenburg
Prof. dr. M.H.M. Heemskerk

Leden promotiecommissie

Prof. dr. R.E.M. Toes
Prof. dr. J.J.C. Neefjes
Prof. dr. I.J.M. de Vries (Radboud Universiteit Nijmegen)
Dr. I. Jedema (Nederlands Kanker Instituut)

TABLE OF CONTENTS

Chapter 1	General introduction and aim of this thesis	9
Chapter 2	A broad and systematic approach to identify B cell malignancy-targeting TCRs for multi-antigen-based T cell therapy <i>Molecular therapy 2022 (published)</i>	31
Chapter 3	Broadly applicable TCR based therapy for multiple myeloma targeting the immunoglobulin J chain <i>Journal of Hematology & Oncology 2023 (published)</i>	73
Chapter 4	T cell receptor-based targeting of immune globulin constant domains for treatment of multiple myeloma <i>Manuscript submitted</i>	103
Chapter 5	Cutting Edge: Unconventional CD8 ⁺ T-cell recognition of a naturally occurring HLA-A*02:01-restricted 20mer epitope <i>The Journal of Immunology 2022 (published)</i>	131
Chapter 6	Summary and general discussion	147
Appendices	Nederlandse samenvatting	169
	List of publications	175
	Curriculum vitae	179
	Dankwoord	181